Like GHRP-6, hexarelin causes a significant, dose-dependent increase in growth hormone. In fact, hexarelin causes a greater increase in growth hormone than the naturally-occurring dose of growth hormone releasing hormone.
There are many studies on the heart function of hexarelin. The peptide has a strong cardioprotective effect, especially in the case of heart damage. In fact, hexarelin has been shown to inhibit apoptosis following myocardial infarction. This, in turn, can reduce the damage to the heart (infarct size) in the short term. A reduction in short-term damage leads to a reduction in scar formation, leading to long-term complications. Mice treated with hexrelin after myocardial ischemia showed improved ejection fraction, reduced vascular resistance and improved outcome compared to controls. More importantly, hexarelin has been shown to reduce atherosclerotic deposition in arteries, improve vascular health and reduce the risk of heart attack and stroke.